諾和諾德股價揚12% 推動OMX哥本哈根20指數上漲6%
OMX哥本哈根20指數周四上漲超過6%,主要受到諾和諾德(NVO.US)股價急劇反彈的推動,此前競爭對手禮來(LLY.US)發佈減重藥效果令人失望。
禮來表示,接受orforglipron治療的患者平均減重12.4%,位於市場對這種備受關注的藥物的預期下限。在禮來的減重藥物試驗結果令市場失望後,諾和諾德的股價大幅上漲。禮來的股價而下跌12%。
諾和諾德的歐洲股價上漲超過12%至324丹麥克朗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.